ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)

P. Malvezzi,1 S. Bunnapradist,2 D. Stevens,3 M. Moten,3 A. Loh,3 S. Patel,3 L. Rostaing.1

1Service De Néphrologie, Hémodialyse, Aphérèses Et Transplantation Rénale, Chu Grenoble Alpes, La Tronche, France
2Nephrology, University of California, Los Angeles, Los Angeles, CA
3Veloxis, Cary, NC.

Meeting: 2018 American Transplant Congress

Abstract number: 522

Keywords: Calcineurin, Immunosuppression, Kidney, Pharmacokinetics

Session Information

Date: Tuesday, June 5, 2018

Session Name: Concurrent Session: Kidney Immunosuppression: General Considerations - 2

Session Time: 4:30pm-6:00pm

 Presentation Time: 4:30pm-4:42pm

Location: Room 6A

Related Abstracts
  • The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
  • A Change in Insulin Sensitivity and Lipid Profile in Renal Transplant Recipients Converted from Cyclosporine or Standard Release Tacrolimus to Once-Daily Prolonged Release Tacrolimus.

LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc analysis of previous conversion studies summarizes the PK profile of LCPT and TacBID when targeted at low, medium, and high trough levels in kidney transplant recipients. Methods: Data from 3 PK studies on conversion from TacBID to LCPT (Gaber 2013, Tremblay 2016, Trofe-Clark 2017) were pooled and patients were grouped according to trough (Cmin) concentrations of ≤5ng/mL, >5 and ≤8ng/mL, or >8 ng/mL. Daily dose conversion rates from TacBID to LCPT ranged from 1:0.7 to 1:0.85. PK parameters between drugs were compared at each trough range. Results: Fifty-three, 115, and 68 patients had trough levels in the low, medium, and high ranges, respectively. Patients treated with LCPT consistently showed lower peaks, less fluctuation, and comparable trough levels in each concentration range (Table 1). Correlation between Cmin and AUC was significant for LCPT in all ranges, but was highest (0.83, p<0.001) in the high trough patients. Conclusion: Pooled analysis of 3 PK studies show that conversion from TacBID to LCPT results in consistently reduced peak concentrations, less fluctuation and similar trough levels at reduced daily doses, regardless of trough level range. Data here demonstrate that LCPT maintains its smoother PK profile with once-daily dosing at a variety of clinically applicable trough targets in kidney transplant recipients.

CITATION INFORMATION: Malvezzi P., Bunnapradist S., Stevens D., Moten M., Loh A., Patel S., Rostaing L. Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT) Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Malvezzi P, Bunnapradist S, Stevens D, Moten M, Loh A, Patel S, Rostaing L. Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT) [abstract]. https://atcmeetingabstracts.com/abstract/tacrolimus-pharmacokinetics-pk-at-low-medium-and-high-trough-levels-in-patients-converted-from-twice-daily-immediate-release-tacrolimus-tacbid-to-once-daily-extended-release-tacrolimus-lcpt/. Accessed January 16, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • How To Handle a Missed or Delayed Dose Intake? A Pharmacokinetic Study of Cyclosporine and Tacrolimus in Renal Transplant Patients
  • How To Handle a Missed or Delayed Dose Intake? A Pharmacokinetic Study of Cyclosporine and Tacrolimus in Renal Transplant Patients
  • Hyperkalemia in the Early Post Renal Transplant Period
  • Direct Oral Anticoagulation Use in Kidney Transplant Recipients

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.